ClinicalTrials.gg
TerminatedNCT00226785Updated Nov 14, 2006

Dexmedetomidine for Continuous Sedation

A Phase 3 interventional study of Dexmedetomidine in Conscious Sedation, sponsored by Orion Corporation, Orion Pharma. Terminated at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-11-14.

Sponsored by Orion Corporation, Orion Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study aims to demonstrate that dexmedetomidine is non-inferior to current best practice sedation with propofol/midazolam and daily sedation stops, in maintaining a target depth of sedation in long-stay intensive care unit (ICU) patients, and that dexmedetomidine, compared with current best practice, reduces the length of ICU stay.

02

Conditions studied

  • Conscious Sedation
03

In context

Lead sponsor

Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical need for sedation and mechanical ventilation
  • Receiving full intensive care life support
  • Expected stay in ICU of at least 48 hours (h) from time of admission
  • Expected requirement for sedation of at least 24h from time of randomisation
  • Written within 36h of ICU admission

Exclusion criteria

Exclusion Criteria:

  • Acute severe neurological disorder
  • Acute uncompensated circulatory failure at time of randomisation
  • Severe bradycardia
  • Atrioventricular (AV) conduction block (II-III) unless pacemaker fitted
  • Severe hepatic impairment
  • Need for muscle relaxation at time of randomisation
  • Loss of hearing or vision or any condition interfering significantly with RASS assessment
  • Positive pregnancy test or currently lactating
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
900 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of time during sedative infusion with a Richmond Agitation Sedation Scale (RASS) score within the individually-prescribed target range

  2. Time from ICU admission to discharge

Secondary outcomes

  1. Nurse's assessment of subject communication

  2. Duration of mechanical ventilation, weaning time and ventilator-free days in ICU

  3. Length of total hospital stay

  4. Functional recovery during hospitalisation

  5. Need for rescue medication to maintain sedation

  6. Frequency of delirium

  7. Frequency of organ failures and failure-free days

  8. Frequency of critical illness polyneuropathy

  9. ICU- and in-hospital survival

  10. Cost of care in the ICU

  11. Total cost of hospitalisation

  12. Blood levels of dexmedetomidine seen with long-term treatment

07

Study locations

4 sites
  • Helsinki University Hospital
    Helsinki, Finland
  • Kuopio University Hospital
    Kuopio, Finland
  • Tampere University Hospital
    Tampere, Finland
  • Inselspital
    Bern, Switzerland
08

References and documents

Publications

  • Ruokonen E, Parviainen I, Jakob SM, Nunes S, Kaukonen M, Shepherd ST, Sarapohja T, Bratty JR, Takala J; "Dexmedetomidine for Continuous Sedation" Investigators. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med. 2009 Feb;35(2):282-90. doi: 10.1007/s00134-008-1296-0. Epub 2008 Sep 16. PubMed 18795253 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2005
First posted
Sep 27, 2005
Start
Oct 2005
Completion
Jul 2006
Last update
Nov 14, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Nov 14, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00226785
First posted
Sep 27, 2005
Start date
Oct 2005
Completion
Jul 2006
Last update
Nov 14, 2006

Study contacts

Jukka Takala, MD, PhD
study chair · University/University Hospital, Bern, Switzerland
Esko Ruokonen, MD, PhD
principal investigator · Kuopio University Hospital, Finland
Stephan Jakob, MD, PhD
principal investigator · University Hospital, Bern, Switzerland
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion